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Abstract
Background: Proximal humeral fractures, which occur mainly in older adults, account for
approximately 4 to 5% of all fractures. Approximately 40% of these fractures are displaced fractures
involving the surgical neck. Management of this group of fractures is often challenging and the
outcome is frequently unsatisfactory. In particular it is not clear whether surgery gives better
outcomes than non-surgical management. Currently there is much variation in the use of surgery
and a lack of good quality evidence to inform this decision.
Methods/Design: We aim to undertake a pragmatic UK-based multi-centre randomised
controlled trial evaluating the effectiveness and cost-effectiveness of surgical versus standard non-
surgical treatment for adults with an acute closed displaced fracture of the proximal humerus with
involvement of the surgical neck. The choice of surgical intervention is left to the surgeon, who
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BMC Musculoskeletal Disorders 2009, 10:140 http://www.biomedcentral.com/1471-2474/10/140must use techniques that they are fully experienced with. This will avoid 'learning curve' problems.
We will promote good standards of non-surgical care, similarly insisting on care-provider
competence, and emphasize the need for comparable provision of rehabilitation for both groups of
patients.
We aim to recruit 250 patients from a minimum of 18 NHS trauma centres throughout the UK.
These patients will be followed-up for 2 years. The primary outcome is the Oxford Shoulder Score,
which will be collected via questionnaires completed by the trial participants at 6, 12 and 24
months. This is a 12-item condition-specific questionnaire providing a total score based on the
person's subjective assessment of pain and activities of daily living impairment. We will also collect
data for other outcomes, including general health measures and complications, and for an economic
evaluation. Additionally, we plan a systematic collection of reasons for non-inclusion of eligible
patients who were not recruited into the trial, and their baseline characteristics, treatment
preferences and intended treatment.
Discussion: This article presents the protocol for a multi-centre randomised controlled trial. It
gives extensive details of, and the basis for, the chosen methods, and describes the key measures
taken to avoid bias and to ensure validity.
Trial Registration: Current Controlled Trials ISRCTN50850043
Background
Rationale for the trial
Proximal humeral fractures account for approximately 4
to 5% of all fractures. Their incidence rapidly increases
with age, and women are affected over twice as often as
men. Similar to other primarily osteoporotic fractures, the
incidence of these fractures is increasing. Palvanen et al.
found a three fold increase over a 33 year period in the
incidence of proximal humeral fractures resulting from
low-energy trauma in people aged 60 and above [1].
A large prospective epidemiology study [2] found that
around half of these fractures (51%) are displaced, when
assessed according to the criteria of Neer's classification
system [3]: one or more parts of the fractured bone are dis-
placed by more than one centimetre, or angulated more
than 45 degrees. Court-Brown et al [2] found that the larg-
est groups of displaced fractures were 2 part surgical neck
fractures (28% of the whole population), followed by 3
part greater tuberosity and surgical neck fractures (9%).
Four part fractures without fracture dislocation were
around 2% of the total. These figures are consistent with
estimates from several members of the trial group.
Recent systematic reviews [4,5], one of which was updated
in 2007 [4], have found a lack of evidence from ran-
domised controlled trials (RCTs) to inform management
decisions for proximal humeral fractures. In particular,
there were only three completed RCTs comparing surgery
with conservative treatment. All were small studies (num-
bers randomised: 30, 32, 40) with flawed methodology.
Both reviews [4,5] concluded that it was unclear whether
operative intervention, even for specific fracture types,
would produce consistently better long-term outcomes.
It is also clear from the literature, confirmed by an infor-
mal survey of the treatment provided by several UK cen-
tres, that there is great variation in the treatment of these
fractures, both in basic (the use of surgery) and specific
(type of implants and surgical technique; non-surgical
management [6] and rehabilitation packages) terms.
Additionally, technology is changing all the time with var-
ious pressures towards early implementation.
The above findings point to a clear need to get reliable evi-
dence to inform practice, and crucially to establish
whether there is a role for operative intervention for the
common types of acute displaced fractures of the proxi-
mal humerus. This is the focus of this trial.
Trial aim
We aim to conduct a pragmatic multi-centre randomised
controlled trial (RCT) to obtain good quality evidence of
effectiveness and cost-effectiveness of surgical versus non-
surgical treatment for the majority of displaced fractures
of the proximal humerus in adults.
Methods
Overview
As indicated, we intend to undertake a pragmatic ran-
domised clinical trial evaluating the effectiveness and
cost-effectiveness of surgical intervention versus standard
conservative therapy for the treatment of the majority of
displaced (all involving the surgical neck) proximal
humeral fractures in adults. This includes the systematic
collection of reasons for non-inclusion of eligible patients
who were not recruited into the trial, and their baseline
characteristics, treatment preferences and intended treat-
ment.Page 2 of 11
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• There is a general dearth of reliable evidence to inform
on the use of surgery (definitive treatment) for patients
with these fractures.
• There are known difficulties in recruitment and particu-
larly patient (and surgeon) preferences. Based on experi-
ence from previous studies, some abandoned, in this
field, we anticipated that a large proportion of eligible
individuals are likely to refuse to be randomised because
they (or their surgeons) will have a strong preference for
one of the study interventions; generally conservative in
the case of patients. On discussions with orthopaedic sur-
geons, lack of clinical equipoise, which is another impor-
tant barrier to performing surgical RCTs [7], is anticipated
to be less of an issue here. Because of these strong prefer-
ences, we consider that it is likely that patients recruited
into any RCT will be a highly selected group, which may
threaten the external validity of our study. Thus, collecting
key data for all patients eligible for the RCT will allow us
to set our randomised results within the context of the
whole patient population and give some pointers to the
applicability of the results of the study.
Proposed use and interpretation of trial results
The trial aims to establish whether surgery yields superior
results to non-surgical treatment. As detailed below, our
protocol emphasizes standardised protocols and care
pathways throughout, comparable and sufficient expertise
of care providers and that the surgeon uses established
techniques with which they are already familiar. Any
questions over whether the use of other surgical methods,
perhaps new methods, would give different results are
countered by two considerations. Firstly, there is an
absence of robust evidence to inform best surgical meth-
ods. Secondly, and arguably, the avoidance of 'learning
curves' and the reliance on surgeon's competence is more
representative of best surgical treatment.
Brief details of the proposed practical arrangements for 
trial recruitment and treatment allocation
A detailed generic scheme of the recruitment process has
been devised for adoption according to local circum-
stances in the participating centres. At radiological review
by the surgeon or their nominated deputy, a trial eligibil-
ity form will be completed for any patient who meets the
trial inclusion criteria. For ineligible patients, the surgeon
is asked to indicate what treatment they would advise for
the patient before the form is sent to the York Trials Unit
(YTU). Those patients who the surgeon indicates as eligi-
ble for the trial will be invited to take part in the trial and
the site-specific patient consent process is initiated. For
non-consenting patients, this fact will be indicated on the
Consent status form, where the surgeon or their deputy is
asked to indicate their advised treatment, the patient's
preferred treatment (if any), and the agreed treatment for
the patient.
Once patients have given consent and their baseline form
completed, the recruiting clinician will contact the York
Trials Unit, either by telephone or via the internet, to
access a secure randomisation service. This will ensure
immediate and unbiased allocation of treatment.
A flowchart showing the patient recruitment and hospital
data collection process is shown in Figure 1.
Proposed methods for avoidance of bias and to ensure 
validity
Randomisation eliminates selection bias: there are, how-
ever, other forms of bias we guard against. We also take
measures to ensure the external validity of trial results. We
will undertake the following:
• Adherence to local guidelines for radiographic assess-
ment will be actively promoted. If not stipulated already,
we will encourage the use of the full shoulder trauma
series [8]. Documentation including a power point pres-
entation illustrating the full trauma series will be made
available as part of the trial materials. A minimum of two
radiographic views/projections is required for the assess-
ment of study eligibility.
• At the end of the recruitment period, there will be scru-
tiny and categorization based on the Neer classification
system, using pre-prepared forms, of the baseline radio-
graphs of all randomised patients. This will be performed
by an independent panel of musculoskeletal radiologists
or orthopaedic surgeons who have experience with the
Neer classification [3]. Copies of radiographs will be pre-
pared beforehand to ensure they are anonymised. On an
on-going basis during trial recruitment there will also be a
review of the quality of the copies of the radiographs for
each trial participant provided by trial centres. This is to
ensure that at the end of trial recruitment the images are
of sufficient quality for the independent panel to assess
and classify the fractures. For the radiographs of the first
five participants at each centre, independent assessment
of the quality of images will be performed by three ortho-
paedic surgeons, one of whom will be the Chief Investiga-
tor. Assessment of the radiographs of subsequent
participants of each centre will be performed by one
orthopaedic surgeon (the Chief Investigator) who, if he
has concerns, will ask the two other independent surgeons
for their comments.
• Clear entry criteria, including checks at randomisation,
will reduce inappropriate entry into the RCT.
• We will endeavour to provide a consistent approach to
recruitment and obtaining informed consent by providingPage 3 of 11
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Flowchart of patient recruitment and hospital data collectionigure 1
Flowchart of patient recruitment and hospital data collection.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 The series of radiographs to confirm the fracture should be e.g. Anteroposterior, Axillary (or modified axillary), Scapular Y-Lateral. 
2 After assessing eligibility, patients may need at least 24 hours to decide about consenting to take part. 
3 Surgical Form also to be completed for any patient randomised to non-surgical treatment who then undergoes surgery. 
4 In-patient Episode Form for a patient not randomised to surgery is not required if patient not admitted to hospital. 
Patients with proximal humerus fractures are assessed1 by 
orthopaedic surgeon for eligibility in fracture clinic or trauma ward 
No consent 
Eligible – obtain consent2 Not eligible 
Complete and post to YTU:    
-  Study Eligibility Form 
Complete following forms: 
-  Study Eligibility Form 
-  Consent Status Form 
-  Consent Form 
-  Baseline Form 
Complete and post to YTU: 
-  Study Eligibility Form 
-  Consent Status Form 
-  Contact randomisation service (online or telephone) to randomise patient and post above forms to YTU 
Surgical Treatment Non-surgical Treatment 
Complete forms and post to YTU within one month from randomisation: 
-  Surgical Form3      -  Treatment Confirmation Form  -  Copies of X-rays 
Complete forms and post to YTU: 
-  In-patient Episode Form4    -  Physiotherapy Treatment Forms 
Complete forms and post to YTU: 
-  One-Year Follow-up Form & Two-Year Follow-up Form 
Patients with proximal humerus fractures will be flagged up by radiology/screened 
by designated person as potentially eligible  
Patient must meet the following inclusion criterion before completing any forms: “Aged 16 or above, presenting 
within three weeks of their injury with a radiologically confirmed displaced fracture of the proximal humerus with 
involvement of the surgical neck”. 
Complete and post to YTU as necessary during the trial: 
-  Adverse Event Form & Trial Exit Form 
Consent 
BMC Musculoskeletal Disorders 2009, 10:140 http://www.biomedcentral.com/1471-2474/10/140an unbiased account of the study to eligible participants
using a specially produced information sheet. These mate-
rials have been produced in collaboration with service
users.
• Concealment of treatment allocation prior to trial entry
will be ensured by use of an independent telephone ran-
domisation service, as provided by the York Trials Unit.
After an initial, prespecified, period of randomisation,
stratified by the presence or not of a tuberosity fracture
and with a prespecified block size, randomisation will
then be performed using a computer generated minimisa-
tion programme. The minimisation factors will be frac-
tures involving either tuberosity and centre.
• We will emphasize good practice and standardised pro-
tocols and care pathways throughout, and comparable
and sufficient expertise of care providers. Surgery for these
types of fractures are usually carried out by consultants;
this has been confirmed by an informal survey of the cen-
tres initially included in our study. We will attempt to
minimise 'learning curve' issues for the surgical interven-
tions by allowing the surgeon to use techniques with
which they are familiar, but prohibiting the introduction
of radically new or experimental methods during the
recruitment period.
• We will encourage the prescription of comparable care,
including rehabilitation programmes, such that any sub-
stantive departures from the norm would reflect the spe-
cial requirements of a specific intervention. Consensus
guidelines for rehabilitation for both groups have been
prepared by rehabilitation specialists and were circulated
for comment and input. These form part of the trial mate-
rials and we will request details of where the prescribed
treatment differs substantively from the standardised pro-
tocols. (See Notes added in clarification below.)
Notes added for clarification
1. Upon discussion, the proposed consensus guidelines for non-
surgical management were considered inappropriate in the con-
text of a pragmatic trial and the lack of evidence to inform prac-
tice. It was decided that the onus should be on the provision of
good standard care and that our approach would be to indicate
both verbally and in the site manual that we would anticipate
initial care to comprise sling immobilisation for about 3 weeks
or for as long as the treating clinician deemed necessary and
active early rehabilitation. We considered that written informa-
tion to advise patients during sling immobilisation was needed
and should be provided to all eligible patients for the trial. We
provide a generic document to be adopted by the hospital should
a suitable document not already be available locally.
2. We stipulate that physiotherapy should be provided equally
to both treatment groups. A consensus protocol giving basic
treatment guidelines has been devised. Although, deviation
from the protocol is allowed and expected, we stipulate that
electrotherapy (except TENS) is not used, and point to an
absence of evidence for these modalities as well as endorsement
via a consultation process with specialist shoulder physiothera-
pists. We will promote the need to encourage home exercises,
but decided not to provide generic information leaflets illustrat-
ing exercises for home use by patients. Instead we will check
that physiotherapists either provide these already or access a
standard web-based facilities to generate 'bespoke' exercise
sheets.
3. We are prospectively collecting details of rehabilitation treat-
ment which will also allow the detection of substantial differ-
ences from the physiotherapy protocol.
• We shall follow the CONSORT guidelines for consider-
ing and reporting RCTs [9,10]. For instance, if eligible
patients decline to be randomised, then this is refusal to
consent (as per CONSORT); if surgeons choose not to ran-
domise an eligible patient then this is a break in protocol
(protocol violation) which must be recorded along with a
reason.
• Intention-to-treat analyses will be undertaken as the pri-
mary analysis in the RCT.
• Active and systematic follow-up of all randomised par-
ticipants at 3, 6, 12 and 24 months is planned. This will
include pre-notification letters as well as the use of
reminders after 2 and 4 weeks. For the 6, 12 and 24 month
follow-ups, there will be an option for completion of an
abridged questionnaire via telephone after 6 weeks. We
will also include an unconditional incentive payment of
€5 to maximize the 12 and 24 month follow-up.
• As far as possible, all participants will be followed-up for
any unplanned events. Their hospital notes will include a
reminder to notify of relevant subsequent treatment/
events and they will be flagged for mortality. With the par-
ticipant's permission, letters will be sent to their General
Practitioners (GP) to inform of participation. Participant's
permission will also be sought to allow us to ask their GP
to provide the participant's contact details should there be
problems contacting them directly.
• There will be independent data entry, processing and
analysis. Aside from accrual and whole populations base-
line statistics, interim results will not be made available to
the trial investigators or associates in the participant cen-
tres.
Data collection on all potentially eligible patients
In addition to the systematic collection of basic baseline
data for those eligible for the RCTs but who did not con-
sent or where there was a protocol violation (reflectingPage 5 of 11
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CONSORT, we will collect data on patient-preferred and
intended management. To complete the CONSORT flow
diagram, we will collect the baseline data and reasons for
ineligibility of ineligible adults presenting in the recruit-
ing centres with the study fractures: see inclusion criteria.
Pilot study
The study was initially set up in Teesside (James Cook
University Hospital, Middlesbrough) for training, and
piloting materials and procedures.
Ethics and impact on trial participants
MREC (Multicentre Research Ethics Committee) approval
has been obtained from York Research Ethics Committee
(reference number 08/H1311/12). Separate approval was
also sought from local research ethics committee for each
centre up until this became the responsibility of NHS
R&D offices from 1st April 2009.
In the context of the lack of robust evidence to determine
the best treatment for patients with these fractures, the
risks are not increased through trial and/or study partici-
pation. Measures, such as our emphasis on good practice
and standardised protocols/care pathways throughout,
taken by us are indeed likely to reduce risk and could
bring additional benefits. We will emphasise the impor-
tance of surgeons performing operations with which they
are familiar and undertake on a regular basis. We will also
stress the importance of competence in conservative
methods, principally rehabilitation. We will adhere to the
good clinical research practice guidelines (MRC and
Research Governance Framework). Our adoption of self
completion questionnaires avoids the need for partici-
pants to specially return for clinical follow-up assess-
ments.
The participant information sheet for the study, which has
been compiled with involvement of service users, gives a
balanced account of the possible benefits and known risks
of the interventions under test. It states explicitly that
quality of care will not be compromised if the participant
decides to a) not enter the trial or b) withdraw their con-
sent. Written informed consent will be obtained from all
participants.
Each trial participant is identified using a unique identifi-
cation number. Patient identifiable information will not
be included in analytical datasets. All relevant trial docu-
mentation will be kept in a secure locality for a minimum
of 20 years.
Participants: planned inclusion/exclusion criteria
Inclusion criteria
Adults (aged 16 or above) presenting to the participating
trauma centre within 3 weeks of their injury with a radio-
graphically confirmed displaced fracture of the proximal
humerus involving the surgical neck. This should include
all 2 part surgical neck fractures; 3 part (including surgical
neck) and 4 part fractures of proximal humerus (Neer
Classification). It may also include displaced surgical neck
fractures that do not meet the exact displacement criteria
of the Neer classification (1 cm or/and 45° angulation of
displaced parts) where this reflects an individual surgeon's
equipoise (e.g., whether the surgical neck fracture should
be treated surgically).
Exclusion criteria
• Associated dislocation of the injured shoulder joint
• Open fracture
• Mentally incompetent patient: unable to understand
trial procedure or instructions for rehabilitation; signifi-
cant mental impairment that would preclude compliance
with rehabilitation and treatment advice
• Co-morbidities precluding surgery/anaesthesia
• A clear indication for surgery such as severe soft-tissue
compromise requiring surgery/emergency treatment
(nerve injury/dysfunction)
• Multiple injuries: same limb fractures; other upper limb
fractures
• Pathological fractures (other than osteoporotic) & ter-
minal illness
• Participant not resident in trauma-centre catchment area
Sample population
This will be all adults (aged 16 or above) presenting
within 3 weeks of injury with fracture types listed in the
inclusion criteria. Ineligible patients will be defined as
those who are excluded for reasons given in the exclusion
criteria. All those who meet the above criteria will be
termed eligible patients. Some patients still may not be
not included in the RCT, for instance due to lack of patient
consent (patient has strong preference for specific treat-
ment option or refuses randomisation) or because the sur-
geon considers one of the treatment options is strongly
indicated for reasons other than above.
Interventions
Each centre participating in this trial has to agree to forgo
the introduction of radically novel and experimental
interventions for these fractures during the recruitment
period.
Central to the obtaining of reliable evidence is that good
standard care, both surgical and non-surgical, is provided
throughout the trial. Where possible, the decisions on the
actual method of surgery, when allocated, and non-surgi-Page 6 of 11
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ipating surgeon. Participating surgeons will be advised
that they should, however, use surgical interventions and
procedures with which they are familiar. This is to avoid
learning curve problems. Similarly, physiotherapists are
advised that they should use procedures with which they
are familiar. The essential components of physiotherapy
at each session will be recorded prospectively.
Surgery
For displaced (2 part) surgical neck fractures: surgical
interventions with which the surgeon is familiar. These
are likely to be plate fixation or intramedullary nailing.
For 3 part (including displaced surgical neck) or 4 part
fractures: surgical interventions with which the surgeon is
familiar. These are likely to include internal fixation such
as nail, plate or other method which preserves the
humeral head; or humeral head replacement (hemi-
arthroplasty). See Figure 2 for an example of a two-part
fracture of the surgical neck and subsequent internal fixa-
tion.
Peri-operative management
Peri-operative management including anaesthesia and
analgesia, antibiotic and thromboembolism prophylaxis,
and dressing policies will follow local guidelines.
Post-operative management
It is envisaged that similar rehabilitation packages, includ-
ing mobilisation protocols, should be provided for all
interventions. Specifically developed guidelines will be
included in the materials for each centre.
Non-surgical intervention (the control group)
Brief recommendations for conservative treatment for
trial participants will be included in the materials for each
centre. Essentially, these advise that conservatively treated
patients will be given sling immobilisation for about 3
weeks or for as long as the treating clinician deems neces-
sary and active early rehabilitation. We will stress the need
for competence in conservative methods, including reha-
bilitation.
Rehabilitation
As far as practical, centres are required to provide written
advice on personal care during sling immobilisation to all
eligible patients. A generic document has been devised
that can be adopted by the centre if required. We will
stress that similar access to physiotherapy should be pro-
vided for surgical and non-surgical participants. A basic
treatment protocol for physiotherapy will be provided.
This will emphasise that, while the protocol acts as a
guide, variation in practice is accepted and anticipated.
Electrotherapy other than TENS will be disallowed. We
will promote strongly the need to encourage patients to
perform home exercises and that they receive information
sheets illustrating how to do the exercises.
Outcome measures
The primary outcome measure is the Oxford Shoulder
Score (OSS) assessed at 6, 12 and 24 months [11]. The
Oxford Shoulder Score is a condition-specific question-
naire providing a total score based on the patient's subjec-
tive assessment of pain and activities of daily living (ADL)
impairment. Consistent with recent developments, the
range of available scores is 0 (worst) to 48 (best) [12]. The
OSS contains 12 items, each with 5 categories of response.
It has been shown to correlate well with both the profes-
sionally-endorsed Constant Score [13] and the SF36
assessment, and to be sensitive to clinical change at six
months after surgical intervention [14]. It has been dem-
onstrated to be consistent, reproducible and valid in a UK
population [11]. This questionnaire will be administered
by post for self-completion by the trial participant with-
out need for an examination and thus avoids the require-
ment for follow-up visits to the clinic for assessment. To
improve compliance, reminders will be sent and patients
will be offered the option of completing the questionnaire
via a telephone call. We will also send pre-notification let-
ters and use unconditional incentives; both have been
shown to be effective at improving response rates [15].
Secondary outcomes are:
• Surgical complications; including shoulder disloca-
tion, failure of implant, proven wound infection
(purulent discharge plus positive bacteriology or need
for revision due to infection), septicaemia (clinical
evidence of systemic infection plus positive blood cul-
tures).
• Early medical complications, i.e. chest infection,
confirmed MI or stroke (confirmed by senior clini-
Two-part fracture of the surgical neck with subsequent inter-nal fixationFigure 2
Two-part fracture of the surgical neck with subse-
quent internal fixation.
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other serious event.
• Mortality, subsequent referral for operation or sub-
stantive treatment.
• The SF12 and Euroqol (EQ-5D) to collect general
health status data (at 6, 12 and 24 months).
Data for economic evaluation
Prospective cost data on trial participants include costs
incurred in hospital and subsequently. Thus, time spent in
theatre and hospital consumables will be collected.
Health utility data will also be obtained from the EQ-5D
collected at 3, 6, 12 and 24 months [16]. Information for
estimating NHS and societal costs will be collected from
the trial participants at each follow-up.
We will collect data on the actual procedures performed,
including anaesthesia, and interventions provided and
the experience of operators/care providers (according to
grade). We will collect these data for all trial participants.
Data collection
We shall aim to make the trial processes as simple as pos-
sible in order to minimise the work entailed at the partic-
ipating centres. As far as possible, we hope to achieve
complete follow-up of all randomised patients.
Baseline data
Basic information including key baseline characteristics
will be collected for all potentially eligible patients (i.e.
those meeting the trial inclusion criteria) who are found
not to be eligible.
Additional data on patient preferences, surgeon's advised
treatment and the agreed treatment will be obtained for
patients who do not consent to trial participation.
For consenting patients, we will collect data on ethnicity,
education, employment, previous fractures, shoulder
dominance, injury mechanism, smoking, diabetes, treat-
ment preference, current health status (EQ-5D), GP name
and surgery and the patient's contact details.
Description of treatment
Surgical methods
Brief details of the actual surgery and procedures used will
be recorded by the surgeon, or assigned deputy, following
the operation. Also prescribed rehabilitation.
Non-surgical methods
Brief details of the prescribed non-surgical treatment will
be recorded by surgeon, or assigned deputy. Also pre-
scribed rehabilitation.
Collection of hospital outcome data - before hospital discharge
Centres will be required to complete data forms detailing:
• Clinical outcomes including surgical complications
and early medical complications
• Resource use: the data on hospital costs will be col-
lected using a cost proforma designed for the trial.
• Substantive deviations from prescribed treatment
and rehabilitation
• Patient destination after hospital discharge
Long term follow-up
One and two year follow-up forms from centres
Forms to notify mortality or subsequent surgery for com-
pletion and return at any time will be made available for
the completion by centre staff. Forms for completion will
be sent at 1 and 2 year follow-up - it is likely that all the
data for these can be gleaned from the hospital records for
these patients.
Follow-up patient questionnaires: 3, 6, 12 and 24 months post trial 
recruitment
A short questionnaire including the EQ-5D and brief
questions on the number of consultations of NHS care
providers (GPs, physiotherapists, district nurses etc), hos-
pitals attendances, use of private healthcare and days lost
from work or other normal activities will be sent together
with a covering letter by the YTU to all participants at
three months. Reply paid envelopes will be included.
Reminders will be sent after 2 and 4 weeks
Full questionnaires, together with covering letters and
reply paid envelopes, will be sent by the YTU to all partic-
ipants at six, 12 and 24 months after recruitment. These
include the Oxford Shoulder Score, EQ-5D and SF12, all
of which are self completion questionnaires. As at 3
months, brief questions on the number of consultations
of NHS care providers (GPs, physiotherapists, district
nurses etc), hospitals attendances, use of private health-
care and days lost from work or other normal activities
will also be requested. Reminders will be sent after 2 and
4 weeks and options for completion of the questionnaires
via telephone after 6 weeks. If completed over the tele-
phone, only the Oxford Shoulder Score, EQ-5D and infor-
mation on hospital readmissions will be requested. An
unconditional incentive payment of £5 will be sent for the
12 and 24 month follow-ups [15].
Radiographs
Copies of all baseline radiographs for all randomised
patients will be requested for independent and blinded
assessment at the end of study recruitment. RadiographsPage 8 of 11
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during trial recruitment to ensure the images are of suffi-
cient quality for scrutiny and classification based on the
Neer classification system by an independent panel of
experts at the end of recruitment.
Sample size
The primary outcome for the trial is differences in
patients' subjective assessments of pain and activities of
daily living (ADL) as measured by the Oxford Shoulder
Score (OSS). For surgery to be worthwhile, it needs to
demonstrate greater improvements in patient's subjective
assessments of pain and ADL than those for conservative
treatment to justify both its increased costs and the expo-
sure to the hazards of surgery. In an observational study
conducted by one of us (AR) it was found that those
patients who had surgery had a 5 point differential
improvement in the OSS compared with those patients
treated conservatively. Given a standard deviation of 12
this equates to an effect size of 0.42. We propose, there-
fore, to design the study to observe an effect size of 0.4 at
80% power using 5% significance level, which would
require approximately 200 participants. After allowing for
drop-outs of 20%, we propose to recruit and randomise
250 patients (125 surgery and 125 controls). Our estimate
of 20% loss from the RCT is purposefully pessimistic for
sample size calculations.
Recruitment rate
We anticipate that recruitment for this trial will be poten-
tially challenging. Therefore, we have set very conservative
recruitment targets. Our recruitment period is 18 months.
We aim to recruit between 18-20 centres. Each centre will
be expected to recruit only one participant per month,
though encouraged to aim higher than this. We estimate
across 18 centres there will be 6066 patients (6000 is used
as a working figure here) with a proximal humeral fracture
over the 18 months of recruitment. Of these, 2391 (thus,
2400 is used as a working figure below) will have the frac-
ture types suitable for inclusion into the RCT. To achieve
our sample size we need to recruit only 11% of these
patients.
Loss to follow-up
We anticipate that the main reason for loss to follow-up
will be mortality. We will follow up patients assiduously
using postal questionnaires and in the event of non-
response we will contact their GP to ascertain whether it is
appropriate to contact the patient and, if so, their address.
Statistical analysis
All of the analyses will use the intention-to-treat principle.
Consequently, any patients who cross over from either
study arm will be analysed as per their randomisation sta-
tus. The primary outcome is the Oxford Shoulder Score
(OSS). The difference between the two treatment groups
will be compared over all follow-up assessments (i.e. 6, 12
and 24 months) using a repeated measures model. The
model will include terms for treatment, follow-up time,
and also adjust for type of fracture, age and gender (as
older people and women are more likely to sustain these
fractures). Because participants are clustered by surgical
centre there is a theoretical possibility that there may be a
'surgeon' effect. We will therefore repeat the primary anal-
ysis using appropriate statistical techniques (robust stand-
ard errors) to account for the clustering of patients within
surgeon. The anonymity of individual surgeons and cen-
tres will be preserved for all analyses and there will be no
presentation or comparisons of the treatment results from
individual centres or surgeons. Subgroup analyses based
on the Neer classification system are planned to assess the
effectiveness of treatment for the different fracture groups
(2 part surgical neck; 3 part including surgical neck and 4
part fractures; fractures not meeting the Neer classification
displacement criteria). The secondary outcomes will be
summarised for each treatment group.
Frequency of analyses
We anticipate that there will be a single analysis at the end
of the study. However, decisions about the need for
interim analysis will be taken by the chair of the inde-
pendent Trial Steering Committee (TSC) in conjunction
with the chair of the Data Monitoring and Ethics Commit-
tee (DMEC).
Assessment of study recruitment and applicability
We will report the numbers of and reasons for ineligible
adults (aged 16 or above) with the study fractures, we will
also report the numbers of and reasons for the non-inclu-
sion of potentially eligible patients. We will compare the
baseline characteristics, patient preferences with those of
randomised patients.
Economic evaluation
An economic analysis will be taken from the perspective
of the UK National Health Service and Social Services. The
horizon for the baseline analysis will be two years. How-
ever, we will model any potential benefits forward to 5
years and an average lifetime in a sensitivity analysis.
Health benefits for the economic analysis will be meas-
ured in terms of quality adjusted life years (QALYs).
Health utility values for individuals with displaced proxi-
mal humeral fractures will be estimated using the Euroqol
(EQ-5D) questionnaire. QALYs will be calculated for each
patient using the area under the curve defined by her/his
EQ-5D scores over the two-year follow-up period and
adjusted by the Kaplan Meier estimates of patients' sur-
vival over the same period of time. Given the horizon forPage 9 of 11
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will be applied to health benefits [17].
Resource use and clinical data will be collected for all trial
participants. Information regarding total volume of
resources used in the treatment (conservative/surgical)
and rehabilitation procedures will be recorded for each
patient. Unit cost will then be applied to estimate the total
cost per patient. To account for the censored nature of cost
data, the Lin method will be used to estimate the mean
average total cost per treatment arm [18]. Non parametric
bootstrapping techniques will be used to estimate 95%
confidence intervals for the mean differential cost
between conservative and surgical treatment [19]. Total
cost will be discounted using a 6% annual discount rate
[17].
Health benefits and mean average total costs associated
with each of the trial arms will be combined in a cost-util-
ity analysis, incremental costs per quality ratios will be
computed comparing the conservative and surgical treat-
ment interventions for adult patients with a displaced
proximal humeral fracture. Multilevel modelling will be
used to explore potential variations in treatment effect
and costs between health professionals [20].
Trial timeline
After a six-month period for trial preparation, obtaining
ethics approval, and establishing and piloting of all trial
materials and processes, the official start date for full-trial
recruitment was set at 1st October 2008. The planned
recruitment period is 18 months, and completion of fol-
low-up 24 months after that. Study completion, which
includes submission of the draft trial report to the funders
for publication in the HTA Journal Series, is scheduled for
1st October 2012.
Dissemination of trial findings
We shall disseminate our findings through relevant local,
national and international conferences and peer-reviewed
publications. Reflecting the collaborative basis of this
research, all active contributors will be named and cred-
ited in the main report.
Trial management
The day to day management of the project is the responsi-
bility of the Trial Management Group:
• Clinical co-ordination: Amar Rangan (Chief Investi-
gator)
• Trial management: Stephen Brealey (Trial Manager,
University of York) and Laura Dennis (Trial Co-ordi-
nator, Teesside University)
• Methodological support: Helen Handoll (Teesside
University), David Torgerson (University of York)
The trial co-ordinating centre is York Trials Unit. Specifi-
cally assigned to the ProFHER trial are a Statistician (Mrs
Gill Worthy, replaced by Dr Catherine Hewitt (April
2009)), a Health Economist (Dr Jo Dumville, replaced by
Miss Ling-Hsiang Chuang (May 2009)), Data Managers
(Mr Ben Cross and Mrs Valerie Wadsworth), and a Trial
Secretary (Mrs Sarah Gardner).
Discussion
This article describes version 7.0 (19/05/09) of the proto-
col for the ProFHER trial. Various adjustments, all
approved by ethics, have been made to the original proto-
col approved by ethics. Many changes were clarifications
in wording. A few others were in response to feedback,
such as from the independent members of the Trial Steer-
ing Committee, and to overcome practical barriers in trial
recruitment. An example of changes is presented in Notes
added for clarification in the Methods section. All changes,
which have been fully documented, are likely to improve
the prospects of the trial successfully meeting its aims.
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